Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Abattis Announces $105,000 Private Placement

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/30/12 -- Abattis Bioceuticals Corp. (CNSX:FLU) (the "Company" or "Abattis") is pleased to announce a non-brokered private placement of up to 2,100,000 units of the Company (the "Units") at a price of $0.05 per Unit for gross proceeds of up to $105,000. Each Unit will be comprised of one common share of the Company and one share purchase warrant. Each warrant will entitle the holder to purchase one additional common share at a price of $0.13 per share for a period of one year, subject to forced acceleration in the event the Company's shares close at a price of $0.20 or higher per share on the Canadian National Stock Exchange (or such other stock exchange as the majority of the trading volume of the Company's shares occur) for 10 consecutive trading days.

Certain directors and officers of the Company may acquire securities under the private placement. A finder's fee of a combination of cash, shares and/or warrants will be paid to eligible finders in relation to this financing, all in accordance with regulatory policies.

The proceeds of this private placement will be used for the general working capital purposes.

The above financing is subject to regulatory approval.

About Abattis Bioceuticals Corp.

Abattis Bioceutical Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients for use in BioPharma, Nutraceutical, Cosmetic and Animal Nutrition markets. The Company has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

ON BEHALF OF THE BOARD

Michael Withrow, President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Abattis Bioceuticals Corp.
Michael Withrow
President & CEO
778-710-9248
604-538-6658 (FAX)
www.abattis.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Despite the data privacy protections supposedly conferred by regulations like HIPAA and HITECH, consumers’ confidential health and personal information is still not safe enough. That’s the lesson to be learned from Franklin, TN-based Community Health Systems’ (CHS) August 18 regulatory...
Most forward-looking CEOs have already made their move to prepare for the future that they foresee – where business technology is a key deciding factor for them to attain ongoing commercial prosperity. This new digital-propelled environment will profoundly change business processes, al...
Last week I told you about my family’s experience with an under the skin glucose sensor that tracks blood sugar levels. While this Internet of Things trend often takes the form of a thermostat, light bulb or coffee machine, the medical field has been using sensors for a while and it is...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...

The "internet of things" is not coming. It's here.

Driven by the introduction of low-cost "things" that are actually useful, Silicon Valley's promised land of a wirelessly-linked network of ev...

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE